{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Breakthrough Therapy: A New Dawn in OSA Treatment \ud83d\ude2e\u200d\ud83d\udca8\u27a1\ufe0f\ud83d\ude34","description":"\ud83d\ude34\ud83d\udc8a Could a pill transform the treatment of obstructive sleep apnea? &amp;nbsp; The SynAIRgy Phase 3 trial of AD109 (aroxybutynin + atomoxetine) showed significant reductions in apnea\u2013hypopnea index and hypoxic burden in patients unable to tolerate CPAP therapy. \ud83c\udf19\ud83e\udec1 &amp;nbsp; A once-nightly oral therapy targeting upper airway neuromuscular dysfunction may represent a new frontier in sleep medicine. Fascinating data with important implications for cardiovascular and metabolic health. \ud83e\udec0\ud83d\udcca &amp;nbsp; #SleepApnea #OSA #AD109 #SleepMedicine #RespiratoryMedicine #MedicalPodcasts #ClinicalTrials #PrecisionMedicine ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41349970\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/202120335"}